Fig. 4
Mortality status. a Kaplan Meier survival curves for patients with CMET (solid line) and cancer-matched controls (dotted line), demonstrating increased mortality among patients with CMET compared to (CMET -) controls matched for primary cancer type and stage (p = 0.004). b Kaplan–Meier curves among sub-groups with heterogeneously (left) and diffusely enhancing (right) CMET as compared to respective cancer-matched controls. Note that prognosis varied based on CMET tissue properties, as evidenced by equivalent mortality risk between diffusely enhancing CMET and controls (p = 0.21) but increased mortality for patients with heterogeneously enhancing lesions (p = 0.004)